Filippo Moriggia was appointed Vice President Operations of Newron effective July 1st, 2022. He has held several management positions, including IT, HR and compliance responsibilities, since he joined Newron in 2016. He has more than 15 years of experience as an IT professional advisor. He started his career as a technical editor for different national magazines of the Mondadori Group. He holds a master degree in Engineering from the Politecnico di Milano and is a licensed professional engineer since 2005. Filippo Moriggia is Italian. 

Dennis Dionne has been Vice President of Commercial Affairs since January 2017. He joined Newron Pharmaceuticals as Executive Director of Commercial Operations in 2015. Dennis has tremendous experience in the CNS arena and served in a variety of commercial leadership roles at Johnson & Johnson (21 years), at Novartis (6 years) has pioneered a number of small venture start-ups.

Stefan Weber was appointed Chief Executive Officer and Executive Director of Newron in 2012. He had been Chief Financial Officer of the Company since April 2005. Stefan holds a master’s degree in business management from FernUniversität Hagen (Diplom-Kaufmann). He has more than 30 years of industry experience in finance and general management. From 2001 to 2005, he was the Chief Financial Officer of Biofrontera, a company active in drug discovery and development.

Roberto Galli was appointed Chief Financial Officer of Newron effective July 1st, 2023. He has been Vice President Finance of the Company since 2012. He has more than 20 years of experience in industry finance and auditing. He joined Newron in 2002.

Laura Faravelli was appointed VP Business Development on July 1, 2023. Since 2015, Laura has held various management roles in Newron’s business development function.  She has over 20 years of experience in international research, development and regulatory approval of new products for central nervous system indications and in drug repositioning.

Ravi Anand, a Swiss resident, has been the Company’s Chief Medical Officer since 2005. He received his university education in New Delhi, India, and his medical training, specialising in psychiatry and neurology, in the U.S. For over 20 years, Ravi has worked in international drug development and regulatory affairs at major pharmaceutical companies, including F. Hoffmann-La Roche (Switzerland), Sandoz/Novartis (US) and Organon (Netherlands). From 1993 to 1997, Ravi was the Medical Director of CNS, Clinical Research at Sandoz Research Institute.